Drug Combination Details
| General Information of the Combination (ID: C82062) | |||||
|---|---|---|---|---|---|
| Name | Farnesol | + | Ibandronate + Docetaxel | ||
| Click to Show/Hide the Each NP or Drug Information of This Combination | |||||
| Name | Farnesol NP Info | Drug Info | |||
| Structure |
|
|
|||
| Name | Drug Info | ||||
| Structure |
|
|
|||
| Disease |
Prostate cancer
[ICD-11: 2C82]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| In-vitro Model | LNCaP | CVCL_0395 | Prostate carcinoma | Homo sapiens | ||
| PC-3 | CVCL_0035 | Prostate carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Ibandronate effectively inhibits growth of prostate cancer cell lines via inhibition of the farnesyl-IPP-synthase and exhibits synergistic effects with docetaxel. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Differential effects of ibandronate, docetaxel and farnesol treatment alone and in combination on the growth of prostate cancer cell lines. Acta Oncol. 2011 Jan;50(1):127-33. | |||
